Energetic basis for drug resistance of HIV-1 protease mutants against amprenavir

Amprenavir (APV) is a high affinity (0.15 nM) HIV-1 protease (PR) inhibitor. However, the affinities of the drug resistant protease variants V32I, I50V, I54V, I54M, I84V and L90M to amprenavir are decreased 3 to 30-fold compared to the wild-type. In this work, the popular molecular mechanics Poisson-Boltzmann surface area method has been used to investigate the effectiveness of amprenavir against the wild-type and these mutated protease variants. Our results reveal that the protonation state of Asp25/Asp25′ strongly affects the dynamics, the overall affinity and the interactions of the inhibitor with individual residues. We emphasize that, in contrast to what is often assumed, the protonation state may not be inferred from the affinities but requires pKa calculations. At neutral pH, Asp25 and Asp25′ are ionized or protonated, respectively, as suggested from pKa calculations. This protonation state was thus mainly considered in our study. Mutation induced changes in binding affinities are in agreement with the experimental findings. The decomposition of the binding free energy reveals the mechanisms underlying binding and drug resistance. Drug resistance arises from an increase in the energetic contribution from the van der Waals interactions between APV and PR (V32I, I50V, and I84V mutant) or a rise in the energetic contribution from the electrostatic interactions between the inhibitor and its target (I54M and I54V mutant). For the V32I mutant, also an increased free energy for the polar solvation contributes to the drug resistance. For the L90M mutant, a rise in the van der Waals energy for APV-PR interactions is compensated by a decrease in the polar solvation free energy such that the net binding affinity remains unchanged. Detailed understanding of the molecular forces governing binding and drug resistance might assist in the design of new inhibitors against HIV-1 PR variants that are resistant against current drugs.

[1]  Tong Zhu,et al.  Some insights into mechanism for binding and drug resistance of wild type and I50V V82A and I84V mutations in HIV-1 protease with GRL-98065 inhibitor from molecular dynamic simulations. , 2010, European journal of medicinal chemistry.

[2]  R. Dixon,et al.  Human immunodeficiency virus protease. Bacterial expression and characterization of the purified aspartic protease. , 1989, The Journal of biological chemistry.

[3]  Jacob Kongsted,et al.  An improved method to predict the entropy term with the MM/PBSA approach , 2009, J. Comput. Aided Mol. Des..

[4]  Irene T. Weber,et al.  Amprenavir complexes with HIV‐1 protease and its drug‐resistant mutants altering hydrophobic clusters , 2010, The FEBS journal.

[5]  Holger Gohlke,et al.  The Amber biomolecular simulation programs , 2005, J. Comput. Chem..

[6]  P. Kollman,et al.  Binding of a diverse set of ligands to avidin and streptavidin: an accurate quantitative prediction of their relative affinities by a combination of molecular mechanics and continuum solvent models. , 2000, Journal of medicinal chemistry.

[7]  P. Kollman,et al.  Computational study of protein specificity: The molecular basis of HIV-1 protease drug resistance , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Allan J. Hance,et al.  HIV Drug Resistance , 2004 .

[9]  Jörg Weiser,et al.  Fast, approximate algorithm for detection of solvent‐inaccessible atoms , 1999 .

[10]  G. Ciccotti,et al.  Numerical Integration of the Cartesian Equations of Motion of a System with Constraints: Molecular Dynamics of n-Alkanes , 1977 .

[11]  Irene T Weber,et al.  Molecular dynamics simulations of 14 HIV protease mutants in complexes with indinavir , 2004, Journal of molecular modeling.

[12]  Martine Peeters,et al.  Genetic Diversity of Protease and Reverse Transcriptase Sequences in Non-Subtype-B Human Immunodeficiency Virus Type 1 Strains: Evidence of Many Minor Drug Resistance Mutations in Treatment-Naive Patients , 2000, Journal of Clinical Microbiology.

[13]  R. Lipowsky,et al.  Importance of polar solvation for cross-reactivity of antibody and its variants with steroids. , 2011, The journal of physical chemistry. B.

[14]  J A McCammon,et al.  Theoretical calculation of relative binding affinity in host-guest systems. , 1986, Proceedings of the National Academy of Sciences of the United States of America.

[15]  V. Turk,et al.  Human immunodeficiency virus has an aspartic-type protease that can be inhibited by pepstatin A. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[16]  Chi‐Huey Wong,et al.  HIV-1 protease: mechanism and drug discovery. , 2003, Organic & biomolecular chemistry.

[17]  Model amyloid peptide B18 monomer and dimer studied by replica exchange molecular dynamics simulations. , 2010, The journal of physical chemistry. B.

[18]  Peter A. Kollman,et al.  FREE ENERGY CALCULATIONS : APPLICATIONS TO CHEMICAL AND BIOCHEMICAL PHENOMENA , 1993 .

[19]  Supot Hannongbua,et al.  Accurate prediction of protonation state as a prerequisite for reliable MM‐PB(GB)SA binding free energy calculations of HIV‐1 protease inhibitors , 2008, J. Comput. Chem..

[20]  Yusuke Mori,et al.  Structure of HIV-1 protease in complex with potent inhibitor KNI-272 determined by high-resolution X-ray and neutron crystallography , 2009, Proceedings of the National Academy of Sciences.

[21]  Qinggang Zhang,et al.  Insights into drug resistance of mutations D30N and I50V to HIV-1 protease inhibitor TMC-114: Free energy calculation and molecular dynamic simulation , 2010, Journal of molecular modeling.

[22]  C. Brooks,et al.  Constant pH molecular dynamics with proton tautomerism. , 2005, Biophysical journal.

[23]  T. Darden,et al.  Particle mesh Ewald: An N⋅log(N) method for Ewald sums in large systems , 1993 .

[24]  Richard H. Henchman,et al.  Revisiting free energy calculations: a theoretical connection to MM/PBSA and direct calculation of the association free energy. , 2004, Biophysical journal.

[25]  W. L. Jorgensen,et al.  Comparison of simple potential functions for simulating liquid water , 1983 .

[26]  Guodong Hu,et al.  Insights into the functional role of protonation states in the HIV-1 protease-BEA369 complex: molecular dynamics simulations and free energy calculations , 2009, Journal of molecular modeling.

[27]  P. Harrigan,et al.  Superior virological response to boosted protease inhibitor‐based highly active antiretroviral therapy in an observational treatment programme , 2007, HIV medicine.

[28]  Araz Jakalian,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: I. Method , 2000 .

[29]  Celia A Schiffer,et al.  Hydrophobic sliding: a possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. , 2007, Structure.

[30]  Christopher I. Bayly,et al.  Fast, efficient generation of high‐quality atomic charges. AM1‐BCC model: II. Parameterization and validation , 2002, J. Comput. Chem..

[31]  Bhyravabhotla Jayaram,et al.  Free Energy Analysis of the Conformational Preferences of A and B Forms of DNA in Solution , 1998 .

[32]  P. Kollman,et al.  Automatic atom type and bond type perception in molecular mechanical calculations. , 2006, Journal of molecular graphics & modelling.

[33]  S. L. Le Grice,et al.  Processing protease and reverse transcriptase from human immunodeficiency virus type I polyprotein in Escherichia coli , 1988, Journal of virology.

[34]  K. Sharp,et al.  Accurate Calculation of Hydration Free Energies Using Macroscopic Solvent Models , 1994 .

[35]  D. Moss,et al.  Benchmarking pKa prediction , 2006, BMC Biochemistry.

[36]  Peter V Coveney,et al.  Rapid and accurate prediction of binding free energies for saquinavir-bound HIV-1 proteases. , 2008, Journal of the American Chemical Society.

[37]  Jan H. Jensen,et al.  Very fast empirical prediction and rationalization of protein pKa values , 2005, Proteins.

[38]  P. Kollman,et al.  Computational Alanine Scanning To Probe Protein−Protein Interactions: A Novel Approach To Evaluate Binding Free Energies , 1999 .

[39]  Charles J. Eyermann,et al.  NMR and X-ray Evidence That the HIV Protease Catalytic Aspartyl Groups Are Protonated in the Complex Formed by the Protease and a Non-Peptide Cyclic Urea-Based Inhibitor , 1994 .

[40]  Viktor Hornak,et al.  HIV-1 protease flaps spontaneously open and reclose in molecular dynamics simulations. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[41]  Tingjun Hou,et al.  Molecular dynamics and free energy studies on the wild-type and double mutant HIV-1 protease complexed with amprenavir and two amprenavir-related inhibitors: mechanism for binding and drug resistance. , 2007, Journal of medicinal chemistry.

[42]  S. Höfinger,et al.  Theoretical mimicry of biomembranes , 2009, FEBS letters.

[43]  Celia A Schiffer,et al.  Decomposing the energetic impact of drug resistant mutations in HIV-1 protease on binding DRV. , 2010, Journal of chemical theory and computation.

[44]  Giulio Rastelli,et al.  Fast and accurate predictions of binding free energies using MM‐PBSA and MM‐GBSA , 2009, J. Comput. Chem..

[45]  V. Hornak,et al.  Comparison of multiple Amber force fields and development of improved protein backbone parameters , 2006, Proteins.

[46]  Joanna Trylska,et al.  Binding Pathways of Ligands to HIV‐1 Protease: Coarse‐grained and Atomistic Simulations , 2007, Chemical biology & drug design.

[47]  Robert W Shafer,et al.  HIV-1 drug resistance mutations: an updated framework for the second decade of HAART. , 2008, AIDS reviews.

[48]  Thomas D. Wu,et al.  Mutation Patterns and Structural Correlates in Human Immunodeficiency Virus Type 1 Protease following Different Protease Inhibitor Treatments , 2003, Journal of Virology.

[49]  L Wang,et al.  Molecular dynamics and free-energy calculations applied to affinity maturation in antibody 48G7. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[50]  A Tropsha,et al.  Relative binding free energies of peptide inhibitors of HIV-1 protease: the influence of the active site protonation state. , 1995, Journal of medicinal chemistry.

[51]  Jan H. Jensen,et al.  Very fast prediction and rationalization of pKa values for protein–ligand complexes , 2008, Proteins.

[52]  W. C. Still,et al.  Approximate atomic surfaces from linear combinations of pairwise overlaps (LCPO) , 1999 .

[53]  P A Kollman,et al.  Structure and thermodynamics of RNA-protein binding: using molecular dynamics and free energy analyses to calculate the free energies of binding and conformational change. , 2000, Journal of molecular biology.

[54]  Ian M. Brereton,et al.  Ionization states of the catalytic residues in HIV-1 protease , 1996, Nature Structural Biology.

[55]  William A. McLaughlin,et al.  Evaluating the potency of HIV‐1 protease drugs to combat resistance , 2008, Proteins.

[56]  P. Kollman,et al.  Use of MM-PBSA in reproducing the binding free energies to HIV-1 RT of TIBO derivatives and predicting the binding mode to HIV-1 RT of efavirenz by docking and MM-PBSA. , 2001, Journal of the American Chemical Society.

[57]  P A Kollman,et al.  Free energy calculations on dimer stability of the HIV protease using molecular dynamics and a continuum solvent model. , 2000, Journal of molecular biology.

[58]  P. Schwille,et al.  Focus on composition and interaction potential of single‐pass transmembrane domains , 2010, Proteomics.

[59]  D. Richman,et al.  2022 update of the drug resistance mutations in HIV-1. , 2022, Topics in antiviral medicine.

[60]  E. Padlan,et al.  Binding of a reduced peptide inhibitor to the aspartic proteinase from Rhizopus chinensis: implications for a mechanism of action. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[61]  P. Kollman,et al.  Investigating the binding specificity of U1A-RNA by computational mutagenesis. , 2000, Journal of molecular biology.

[62]  Supot Hannongbua,et al.  Insights into saquinavir resistance in the G48V HIV-1 protease: quantum calculations and molecular dynamic simulations. , 2005, Biophysical journal.

[63]  Jan Hermans,et al.  Discrimination between native and intentionally misfolded conformations of proteins: ES/IS, a new method for calculating conformational free energy that uses both dynamics simulations with an explicit solvent and an implicit solvent continuum model , 1998, Proteins.

[64]  Junmei Wang,et al.  Development and testing of a general amber force field , 2004, J. Comput. Chem..

[65]  P. Kollman,et al.  Calculating structures and free energies of complex molecules: combining molecular mechanics and continuum models. , 2000, Accounts of chemical research.

[66]  D. Case,et al.  Insights into protein-protein binding by binding free energy calculation and free energy decomposition for the Ras-Raf and Ras-RalGDS complexes. , 2003, Journal of molecular biology.

[67]  Dennis R. Burton,et al.  Toward an AIDS Vaccine , 2008, Science.